INDICATIONS: This product has been shown to be effective for the vaccination of healthy chickens 12 weeks of age or older against fowl cholera caused by *Pasteurella multocida* serotype 1. The duration of immunity has not been established. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Vaxxon® and Vaxxinova® are registered trademarks of Vaxxinova International, B.V., the Netherlands. SRP® is a registered trademark of Vaxxinova US. © 2021

P05-032021 - Vaxxon SRP Pasteurella Detailer

For more information on Vaxxon SRP Pasteurella, please visit our website at www.vaxxinova.us.com

vaxxinova®

Vaxxinova, 1801 Biotech Ave NE, Willmar, MN 56201
844-SRP-VAXX | www.vaxxinova.us.com

vaxxinova®

Vaxxon® SRP® Pasteurella

Siderophore Receptors and Porins

SRP

Vaxxon® SRP® Pasteurella is an effective, innovative and safe vaccine against fowl cholera caused by *P. multocida* in chickens. The vaccine utilizes Vaxxinova's SRP® (siderophore receptor and porin) protein technology that provides optimal protection.

SRP vaccines are derived from common proteins involved in the iron acquisition system of bacteria. Unlike other, inactivated fowl cholera vaccines on the market today, these are not serotype-dependent.

Table 1. Efficacy of Vaxxon® SRP® Pasteurella – Pasteurella Multocida Bacterial Extract Vaccine in chickens challenged with *P. multocida* serotype 1 (X-73 isolate).



EFFICACY: The efficacy of Vaxxon SRP Pasteurella was demonstrated in a vaccination-and-challenge study as mandated by USDA.[1] Forty (40) specific pathogen free (SPF) leghorn chickens were randomly divided into two treatment groups, Vaxxon SRP Pasteurella vaccine and Placebo. Vaccines were administered subcutaneously (0.25 mL dose/bird) at 12 and 15 weeks of age. The birds were then challenged with 6000 CFU/0.5 mL dose of *P. multocida* Type 1 (X-73 strain) at 17 weeks of age. Birds were observed daily, and mortality was recorded during the 2 weeks post-challenge. All birds (20/20) or 100% of birds vaccinated with Vaxxon SRP Pasteurella survived the challenge with no mortality throughout the 2-week period. Only 4/20 birds (20%) in the placebo group survived after challenge. This study confirms the efficacy of Vaxxon SRP Pasteurella in protecting chickens from mortality due to fowl cholera.

SAFETY: The safety of Vaxxon SRP Pasteurella was demonstrated in 59,033 birds during a field safety study.[2] Three different flocks in distinct geographic locations were vaccinated twice with either the Vaxxon SRP Pasteurella vaccine or a commercial vaccine.

There were no adverse events detected following vaccination with Vaxxon SRP Pasteurella. The overall safety of the product was acceptable with the mortality rates numerically lower in the Vaxxon SRP Pasteurella vaccinated birds than their matching Controls (0.48% vs. 0.63%, respectively).

Table 2. Overall mortality during the field safety study observation period, after vaccination with Vaxxon SRP Pasteurella or commercial inactivated bacterin.

Treatment	Number of Birds	Total Mortality	Mortality Rate (%)
Vaxxon SRP Pasteurella	59,033	286	0.48
Controls	56,542	354	0.63

Vaxxon® SRP® Pasteurella is an effective, innovative and safe vaccine against fowl cholera caused by *P. multocida* Type 1.

REFERENCES:

1. Data on file. Study No. 1907, July 22, 2019. Vaxxinova US.
2. Data on file. Study No. 1916, November 11, 2020. Vaxxinova US.